{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T17:18:56Z","timestamp":1778001536641,"version":"3.51.4"},"reference-count":86,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>The advent of direct oral anticoagulants (DOACs) marks a significant milestone in anticoagulant treatment. However, DOACs can exacerbate bleeding, which is challenging for the treating clinician, especially when combined with traumatic injury.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>In major bleeding associated with DOACs, rapid reversal of the anticoagulant effects is crucial. Recent observational and nonrandomized interventional trials have demonstrated the effectiveness of the specific antidotes andexanet alfa and idarucizumab as well as the unspecific prothrombin complex concentrates (PCCs) to counteract the anticoagulant effects of DOACs. The European Society of Anaesthesiology and Intensive Care guideline for severe perioperative bleeding and the European trauma guideline propose divergent recommendations for the use of andexanet alfa and PCC to obtain hemostasis in Factor Xa inhibitor-related bleeding. The conflicting recommendations are due to limited evidence from clinical studies and the potential increased risk of thromboembolic complications after the administration of andexanet. Regarding dabigatran-associated major bleeding, both guidelines recommend the specific reversal agent idarucizumab as first-line therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Current guidelines recommend specific antidots and PCCs in DOAC-related major bleeding. Prospective randomized trials comparing specific vs. nonspecific hemostatic agents in the perioperative setting are needed to evaluate the effectiveness and safety of the hemostatic agents.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/aco.0000000000001349","type":"journal-article","created":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T12:00:33Z","timestamp":1708689633000},"page":"101-109","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Antidote vs. unspecific hemostatic agents for the management of direct oral anticoagulant-related bleeding in trauma"],"prefix":"10.1097","volume":"37","author":[{"given":"Jan","family":"Wienhold","sequence":"first","affiliation":[{"name":"Department of Anaesthesiology, RWTH Aachen University Hospital, Aachen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farahnaz","family":"Rayatdoost","sequence":"additional","affiliation":[{"name":"Department of Anaesthesiology, RWTH Aachen University Hospital, Aachen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herbert","family":"Sch\u00f6chl","sequence":"additional","affiliation":[{"name":"Ludwig Boltzmann Institute for Traumatology, The Research Centre in Cooperation with AUVA, Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Grottke","sequence":"additional","affiliation":[{"name":"Department of Anaesthesiology, RWTH Aachen University Hospital, Aachen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2024,1,19]]},"reference":[{"issue":"(19)","key":"R1-20250601","first-page":"2369","article-title":"Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)","volume":"31","author":"Camm","year":"2010","journal-title":"Eur Heart J"},{"key":"R2-20250601","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation","volume":"146","author":"Hart","year":"2007","journal-title":"Ann Intern Med"},{"issue":"(Suppl)","key":"R3-20250601","doi-asserted-by":"crossref","first-page":"454s","DOI":"10.1378\/chest.08-0658","article-title":"Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition)","volume":"133","author":"Kearon","year":"2008","journal-title":"Chest"},{"key":"R4-20250601","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","article-title":"Dabigatran versus warfarin in the treatment of acute venous thromboembolism","volume":"361","author":"Schulman","year":"2009","journal-title":"N Engl J Med"},{"key":"R5-20250601","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1161\/CIRCULATIONAHA.113.004450","article-title":"Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis","volume":"129","author":"Schulman","year":"2014","journal-title":"Circulation"},{"key":"R6-20250601","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"Bauersachs","year":"2010","journal-title":"N Engl J Med"},{"key":"R7-20250601","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","article-title":"Oral rivaroxaban for the treatment of symptomatic pulmonary embolism","volume":"366","author":"B\u00fcller","year":"2012","journal-title":"N Engl J Med"},{"key":"R8-20250601","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"369","author":"Agnelli","year":"2013","journal-title":"N Engl J Med"},{"key":"R9-20250601","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","article-title":"Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism","volume":"369","author":"B\u00fcller","year":"2013","journal-title":"N Engl J Med"},{"key":"R10-20250601","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1161\/CIRCULATIONAHA.114.012061","article-title":"Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation","volume":"131","author":"Graham","year":"2015","journal-title":"Circulation"},{"key":"R11-20250601","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1161\/CIRCOUTCOMES.115.002369","article-title":"Dabigatran versus warfarin for atrial fibrillation in real-world clinical practice: a systematic review and meta-analysis","volume":"9","author":"Romanelli","year":"2016","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"R12-20250601","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"R13-20250601","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"R14-20250601","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1161\/JAHA.116.003725","article-title":"Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation","volume":"5","author":"Yao","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"R15-20250601","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"R16-20250601","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"key":"R17-20250601","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1093\/eurheartj\/ehv466","article-title":"XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation","volume":"37","author":"Camm","year":"2016","journal-title":"Eur Heart J"},{"key":"R18-20250601","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"R19-20250601","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1161\/STROKEAHA.112.650614","article-title":"Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial","volume":"43","author":"Hart","year":"2012","journal-title":"Stroke"},{"key":"R20-20250601","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.amjmed.2006.07.034","article-title":"Death and disability from warfarin-associated intracranial and extracranial hemorrhages","volume":"120","author":"Fang","year":"2007","journal-title":"Am J Med"},{"key":"R21-20250601","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"23","author":"Steffel","year":"2021","journal-title":"Europace"},{"key":"R22-20250601","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3390\/medicines8040016","article-title":"Trauma-induced coagulopathy: overview of an emerging medical problem from pathophysiology to outcomes","volume":"8","author":"Savioli","year":"2021","journal-title":"Medicines"},{"key":"R23-20250601","doi-asserted-by":"crossref","first-page":"445","DOI":"10.3390\/biomedicines9050445","article-title":"Laboratory monitoring of direct oral anticoagulants (DOACs)","volume":"9","author":"Dunois","year":"2021","journal-title":"Biomedicines"},{"key":"R24-20250601","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13054-023-04327-7","article-title":"The European guideline on management of major bleeding and coagulopathy following trauma: sixth edition","volume":"27","author":"Rossaint","year":"2023","journal-title":"Crit Care"},{"key":"R25-20250601","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/EJA.0000000000001803","article-title":"Management of severe peri-operative bleeding: guidelines from the European Society of Anaesthesiology and Intensive Care: Second update 2022","volume":"40","author":"Kietaibl","year":"2023","journal-title":"Eur J Anaesthesiol"},{"key":"R26-20250601","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1056\/NEJMoa1510991","article-title":"Andexanet alfa for the reversal of factor Xa inhibitor activity","volume":"373","author":"Siegal","year":"2015","journal-title":"N Engl J Med"},{"key":"R27-20250601","doi-asserted-by":"crossref","first-page":"1076029619863493","DOI":"10.1177\/1076029619863493","article-title":"Reversal of factor Xa inhibitors by andexanet alfa may increase thrombogenesis compared to pretreatment values","volume":"25","author":"Siddiqui","year":"2019","journal-title":"Clin Appl Thromb Hemost"},{"key":"R28-20250601","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1182\/bloodadvances.2019000885","article-title":"A phase 2\u200aPK\/PD study of andexanet alfa for reversal of rivaroxaban and edoxaban anticoagulation in healthy volunteers","volume":"4","author":"Lu","year":"2020","journal-title":"Blood Adv"},{"key":"R29-20250601","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1182\/bloodadvances.2017007112","article-title":"Safety, pharmacokinetics, and reversal of apixaban anticoagulation with andexanet alfa","volume":"1","author":"Siegal","year":"2017","journal-title":"Blood Adv"},{"key":"R30-20250601","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1111\/jth.13768","article-title":"Preclinical safety and efficacy of andexanet alfa in animal models","volume":"15","author":"Lu","year":"2017","journal-title":"J Thromb Haemost"},{"key":"R31-20250601","doi-asserted-by":"crossref","first-page":"2042098619888133","DOI":"10.1177\/2042098619888133","article-title":"Andexanet alfa for reversal of factor Xa inhibitor-associated anticoagulation","volume":"10","author":"Carpenter","year":"2019","journal-title":"Ther Adv Drug Saf"},{"issue":"(Suppl 1)","key":"R32-20250601","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1182\/blood.V130.Suppl_1.629.629","article-title":"Effect of andexanet-TFPI interaction on in vitro thrombin formation and coagulation markers in the TF-pathway","volume":"130","author":"Lu","year":"2017","journal-title":"Blood"},{"key":"R33-20250601","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1056\/NEJMoa1814051","article-title":"Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors","volume":"380","author":"Connolly","year":"2019","journal-title":"N Engl J Med"},{"key":"R35-20250601","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1055\/s-0041-1740180","article-title":"Andexanet alfa for specific anticoagulation reversal in patients with acute bleeding during treatment with edoxaban","volume":"122","author":"Benz","year":"2022","journal-title":"Thromb Haemost"},{"key":"R36-20250601","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nm.3102","article-title":"A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa","volume":"19","author":"Lu","year":"2013","journal-title":"Nat Med"},{"key":"R37-20250601","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1182\/blood.V126.23.2329.2329","article-title":"Reversal of heparin-induced anticoagulation by andexanet Alfa, a universal antidote for factor Xa inhibitors","volume":"126","author":"Lu","year":"2015","journal-title":"Blood"},{"key":"R38-20250601","doi-asserted-by":"crossref","first-page":"390","DOI":"10.5811\/cpcem.2019.9.43650","article-title":"Difficult intraoperative heparinization following andexanet alfa administration","volume":"3","author":"Watson","year":"2019","journal-title":"Clin Pract Cases Emerg Med"},{"key":"R39-20250601","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1213\/XAA.0000000000001052","article-title":"Andexanet alfa for urgent reversal of apixaban before aortic surgery requiring cardiopulmonary bypass: a case report","volume":"13","author":"Flaherty","year":"2019","journal-title":"A&A Pract"},{"key":"R40-20250601","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1002\/phar.2306","article-title":"Intraoperative unfractionated heparin unresponsiveness during endovascular repair of a ruptured abdominal aortic aneurysm following administration of andexanet alfa for the reversal of rivaroxaban","volume":"39","author":"Eche","year":"2019","journal-title":"Pharmacotherapy"},{"key":"R41-20250601","doi-asserted-by":"crossref","first-page":"e1025","DOI":"10.1097\/CCM.0000000000005059","article-title":"Andexanet alfa or prothrombin complex concentrate for factor Xa inhibitor reversal in acute major bleeding: a systematic review and meta-analysis","volume":"49","author":"Nederpelt","year":"2021","journal-title":"Crit Care Med"},{"key":"R42-20250601","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1016\/j.jacc.2021.04.061","article-title":"Meta-analysis of reversal agents for severe bleeding associated with direct oral anticoagulants","volume":"77","author":"G\u00f3mez-Outes","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"R43-20250601","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1111\/jth.14838","article-title":"Evaluation of andexanet alfa and four-factor prothrombin complex concentrate (4F-PCC) for reversal of rivaroxaban- and apixaban-associated intracranial hemorrhages","volume":"18","author":"Barra","year":"2020","journal-title":"J Thromb Haemost"},{"key":"R44-20250601","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1161\/CIRCULATIONAHA.121.057844","article-title":"Final study report of andexanet alfa for major bleeding with factor Xa inhibitors","volume":"147","author":"Milling","year":"2023","journal-title":"Circulation"},{"key":"R45-20250601","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/ijlh.13591","article-title":"Measuring residual anti-Xa activity of direct factor Xa inhibitors after reversal with andexanet alfa","volume":"43","author":"Bourdin","year":"2021","journal-title":"Int J Lab Hematol"},{"key":"R48-20250601","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1182\/blood-2012-11-468207","article-title":"A specific antidote for dabigatran: functional and structural characterization","volume":"121","author":"Schiele","year":"2013","journal-title":"Blood"},{"key":"R49-20250601","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/S0140-6736(15)60732-2","article-title":"Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial","volume":"386","author":"Glund","year":"2015","journal-title":"Lancet"},{"key":"R50-20250601","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1056\/NEJMoa1707278","article-title":"Idarucizumab for dabigatran reversal \u2013 full cohort analysis","volume":"377","author":"Pollack","year":"2017","journal-title":"N Engl J Med"},{"key":"R51-20250601","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.bja.2018.04.025","article-title":"Ongoing redistribution of dabigatran necessitates repetitive application of idarucizumab","volume":"121","author":"Hegemann","year":"2018","journal-title":"Br J Anaesth"},{"key":"R52-20250601","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1080\/15563650.2020.1743846","article-title":"Incomplete responses to the recommended dose of idarucizumab: a systematic review and pharmacokinetic analysis","volume":"58","author":"Athavale","year":"2020","journal-title":"Clin Toxicol (Phila)"},{"key":"R53-20250601","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3324\/haematol.2013.092767","article-title":"Use of prothrombin complex concentrates for urgent reversal of dabigatran in the Emergency Department","volume":"98","author":"D\u00edaz","year":"2013","journal-title":"Haematologica"},{"key":"R54-20250601","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/bjh.12620","article-title":"Activated prothrombin complex concentrate for dabigatran-associated bleeding","volume":"164","author":"Schulman","year":"2014","journal-title":"Br J Haematol"},{"key":"R55-20250601","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/CCM.0b013e31827caaa3","article-title":"Reversing dabigatran in life-threatening bleeding occurring during cardiac ablation with factor eight inhibitor bypassing activity","volume":"41","author":"Dager","year":"2013","journal-title":"Crit Care Med"},{"key":"R56-20250601","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1097\/ALN.0000000000000863","article-title":"Prothrombin complex concentrate is effective in treating the anticoagulant effects of dabigatran in a porcine polytrauma model","volume":"123","author":"Honickel","year":"2015","journal-title":"Anesthesiology"},{"key":"R57-20250601","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.thromres.2017.02.010","article-title":"Reversal of dabigatran-associated major bleeding with activated prothrombin concentrate: A prospective cohort study","volume":"152","author":"Schulman","year":"2017","journal-title":"Thromb Res"},{"key":"R58-20250601","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1111\/trf.15259","article-title":"Idarucizumab, but not procoagulant concentrates, fully restores dabigatran-altered platelet and fibrin components of hemostasis","volume":"59","author":"Arellano-Rodrigo","year":"2019","journal-title":"Transfusion"},{"key":"R59-20250601","first-page":"149","article-title":"Prothrombin complex concentrates: an update","volume":"8","author":"Franchini","year":"2010","journal-title":"Blood Transfus"},{"key":"R60-20250601","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1055\/s-0042-1758653","article-title":"3-Factor versus 4-factor prothrombin complex concentrates for the reversal of vitamin K antagonist-associated coagulopathy: a systematic review and meta-analysis","volume":"123","author":"Puchstein","year":"2023","journal-title":"Thromb Haemost"},{"key":"R61-20250601","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1097\/ALN.0000000000002910","article-title":"Four-factor prothrombin complex concentrate for the management of patients receiving direct oral activated factor X inhibitors","volume":"131","author":"Grottke","year":"2019","journal-title":"Anesthesiology"},{"key":"R62-20250601","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/rth2.12089","article-title":"Pharmacological reversal of the direct oral anticoagulants\u2014a comprehensive review of the literature","volume":"2","author":"Shaw","year":"2018","journal-title":"Res Pract Thromb Haemost"},{"key":"R63-20250601","doi-asserted-by":"crossref","first-page":"e12699","DOI":"10.1002\/rth2.12699","article-title":"Reversing direct factor Xa or thrombin inhibitors: factor V addition to prothrombin complex concentrate is beneficial in vitro","volume":"6","author":"Brinkman","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"key":"R64-20250601","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/ajh.25475","article-title":"Reversal of direct oral anticoagulants: guidance from the anticoagulation forum","volume":"94","author":"Cuker","year":"2019","journal-title":"Am J Hematol"},{"key":"R65-20250601","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1111\/jth.12599","article-title":"Comparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers","volume":"12","author":"Levi","year":"2014","journal-title":"J Thromb Haemost"},{"key":"R66-20250601","doi-asserted-by":"crossref","first-page":"175","DOI":"10.33176\/AACB-19-00029","article-title":"(Long-acting anticoagulant rodenticides) poisoning: from pathophysiology to laboratory-guided clinical management","volume":"40","author":"Chong","year":"2019","journal-title":"Clin Biochem Rev"},{"key":"R67-20250601","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/bjh.15808","article-title":"Haematological management of major bleeding associated with direct oral anticoagulants \u2013 UK experience","volume":"185","author":"Green","year":"2019","journal-title":"Br J Haematol"},{"key":"R68-20250601","article-title":"Comparative analysis of andexanet alfa and prothrombin complex concentrate in reversing anticoagulation by rivaroxaban ex vivo","author":"Rayatdoost","year":"2023","journal-title":"Br J Anaesth"},{"key":"R69-20250601","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1161\/CIRCULATIONAHA.120.045769","article-title":"Factor Xa inhibitor-related intracranial hemorrhage: results from a multicenter, observational cohort receiving prothrombin complex concentrates","volume":"141","author":"Panos","year":"2020","journal-title":"Circulation"},{"key":"R70-20250601","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1055\/s-0038-1636541","article-title":"Prothrombin complex concentrate for major bleeding on factor xa inhibitors: a prospective cohort study","volume":"118","author":"Schulman","year":"2018","journal-title":"Thromb Haemost"},{"key":"R71-20250601","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1182\/blood-2017-05-782060","article-title":"Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study","volume":"130","author":"Majeed","year":"2017","journal-title":"Blood"},{"key":"R72-20250601","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1097\/ALN.0000000000002399","article-title":"Prothrombin complex concentrates for perioperative vitamin K antagonist and non\u2013vitamin K anticoagulant reversal","volume":"129","author":"Levy","year":"2018","journal-title":"Anesthesiology"},{"key":"R73-20250601","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1182\/bloodadvances.2018024133","article-title":"Management of direct factor Xa inhibitor-related major bleeding with prothrombin complex concentrate: a meta-analysis","volume":"3","author":"Piran","year":"2019","journal-title":"Blood Adv"},{"key":"R74-20250601","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1097\/ALN.0000000000000608","article-title":"Prothrombin complex concentrates in trauma and perioperative bleeding","volume":"122","author":"Grottke","year":"2015","journal-title":"Anesthesiology"},{"key":"R75-20250601","doi-asserted-by":"crossref","first-page":"R147","DOI":"10.1186\/cc13982","article-title":"Endogenous thrombin potential following hemostatic therapy with 4-factor prothrombin complex concentrate: a 7-day observational study of trauma patients","volume":"18","author":"Sch\u00f6chl","year":"2014","journal-title":"Crit Care"},{"key":"R76-20250601","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1182\/blood-2011-03-343046","article-title":"Increasing concentrations of prothrombin complex concentrate induce disseminated intravascular coagulation in a pig model of coagulopathy with blunt liver injury","volume":"118","author":"Grottke","year":"2011","journal-title":"Blood"},{"key":"R77-20250601","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1097\/ALN.0000000000002797","article-title":"Prothrombin complex concentrate-induced disseminated intravascular coagulation can be prevented by coadministering antithrombin in a porcine trauma model","volume":"131","author":"Grottke","year":"2019","journal-title":"Anesthesiology"},{"key":"R78-20250601","article-title":"Comparison of outcomes for fixed and weight-based four-factor prothrombin complex concentrate dosing regimens","author":"Bittar","year":"2023","journal-title":"Eur J Hosp Pharm"},{"key":"R79-20250601","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1016\/j.ajem.2020.05.086","article-title":"A review of guidelines on anticoagulation reversal across different clinical scenarios \u2013 is there a general consensus?","volume":"38","author":"Milling","year":"2020","journal-title":"Am J Emerg Med"},{"key":"R80-20250601","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1001\/jamainternmed.2019.2431","article-title":"Perioperative management of patients with atrial fibrillation receiving a direct oral anticoagulant","volume":"179","author":"Douketis","year":"2019","journal-title":"JAMA Intern Med"},{"key":"R81-20250601","doi-asserted-by":"crossref","first-page":"411","DOI":"10.21037\/atm.2019.07.101","article-title":"Current status of oral anticoagulant reversal strategies: a review","volume":"7","author":"Rawal","year":"2019","journal-title":"Ann Transl Med"},{"key":"R82-20250601","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1055\/a-1113-0557","article-title":"How do i reverse oral and parenteral anticoagulants?","volume":"40","author":"Koscielny","year":"2020","journal-title":"Hamostaseologie"},{"key":"R83-20250601","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2217\/pme-2017-0092","article-title":"Pharmacogenetics of novel oral anticoagulants: a review of identified gene variants & future perspectives","volume":"15","author":"A\u0161i\u0107","year":"2018","journal-title":"Personal Med"},{"key":"R84-20250601","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1177\/2396987319849763","article-title":"European Stroke Organisation guideline on reversal of oral anticoagulants in acute intracerebral haemorrhage","volume":"4","author":"Christensen","year":"2019","journal-title":"Eur Stroke J"},{"key":"R85-20250601","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jacc.2019.01.011","article-title":"2019\u200aAHA\/ACC\/HRS Focused Update of the 2014\u200aAHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the american College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society","volume":"74","author":"January","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"R86-20250601","doi-asserted-by":"crossref","first-page":"e2240145","DOI":"10.1001\/jamanetworkopen.2022.40145","article-title":"Evaluation of direct oral anticoagulant reversal agents in intracranial hemorrhage: a systematic review and meta-analysis","volume":"5","author":"Chaudhary","year":"2022","journal-title":"JAMA Netw Open"},{"key":"R87-20250601","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s11239-022-02658-w","article-title":"Andexanet alfa after 4-factor PCC administration for intracranial hemorrhage: a case series","volume":"54","author":"Bradshaw","year":"2022","journal-title":"J Thromb Thromb"},{"key":"R88-20250601","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/jth.13894","article-title":"Rivaroxaban reversal with prothrombin complex concentrate or tranexamic acid in healthy volunteers","volume":"16","author":"Levy","year":"2018","journal-title":"J Thromb Haemost"},{"key":"R89-20250601","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1093\/ajhp\/zxac079","article-title":"Four-factor prothrombin complex concentrate plus andexanet alfa for reversal of factor Xa inhibitor-associated bleeding: case series","volume":"79","author":"Liu","year":"2022","journal-title":"Am J Health Syst Pharm"}],"container-title":["Current Opinion in Anaesthesiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/ACO.0000000000001349","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T22:04:55Z","timestamp":1748815495000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/ACO.0000000000001349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,19]]},"references-count":86,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/aco.0000000000001349","relation":{},"ISSN":["0952-7907","1473-6500"],"issn-type":[{"value":"0952-7907","type":"print"},{"value":"1473-6500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,19]]}}}